Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Conditions
Interventions
NTX-1472
Placebo
Locations
11
United States
SOAR Clinical Study Site
Pheonix, Arizona, United States
SOAR Clinical Study Site
Encino, California, United States
SOAR Clinical Study Site
Los Angeles, California, United States
SOAR Clinical Study Site
Oceanside, California, United States
SOAR Clinical Study Site
San Jose, California, United States
SOAR Clinical Study Site
Jacksonville, Florida, United States
Start Date
December 9, 2025
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
January 21, 2026
NCT07456631
NCT07325929
NCT00231348
Lead Sponsor
Newleos Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions